Diferencia entre revisiones de «Sodium polystyrene sulfonate»
(Fix SMW query: use mainlabel=- to hide subobject column with broken fragment links; Indication column links directly to disease page) |
(Switch SMW query from broadtable to table format for better layout with TOC) |
||
| Línea 55: | Línea 55: | ||
|?Has Route=Route | |?Has Route=Route | ||
|?Has Population=Population | |?Has Population=Population | ||
|format= | |format=table | ||
|headers=plain | |headers=plain | ||
|mainlabel=- | |mainlabel=- | ||
Revisión actual - 21:57 20 mar 2026
General
- Type:
- Dosage Forms:
- Common Trade Names: Kayexalate
Adult Dosing
Hyperkalemia
- 30 gm oral or per rectum
Pediatric Dosing
- >1mo: 1 g/kg PO or PR q6hr PRN
Special Populations
- Pregnancy Rating: B
- Lactation: Not absorbed systemically so infant risk minimal
- Renal Dosing
- Adult
- Pediatric
- Hepatic Dosing
- Adult
- Pediatric
Contraindications
- Allergy to class/drug
- Hypokalemia
- Obstructive bowel disease, reduced gut motility
- Rectal administration in neonates, particularly if premature
Adverse Reactions
Serious
- Intestinal necrosis, ulceration, perforation, fecal impaction
- Bezoars
Common
- Abdominal pain, nausea/vomiting, constipation, GI disturbance
- Hypokalemia
- Hypocalcemia
- Hypomagnesemia
- Sodium retention
Pharmacology
- Half-life:
- Metabolism:
- Excretion:
- Mechanism of Action: Cation exchange resin, sodium ions partially released from polystyrene and replaced by potassium
Indications by Condition
The following table is automatically generated from disease/condition pages across WikEM.
See Also
- Alternative Sodium zirconium cyclosilicate (Lokelma)